{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tae CH"],"funding":["Korea United Pharm"],"pagination":["106-115"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10774802"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(1)"],"pubmed_abstract":["<h4>Background/aims</h4>Prokinetic agents and neuromodulators are among the treatment options for functional dyspepsia (FD), but their comparative efficacy is unclear. We aimed to compare the efficacy of mosapride controlled-release (CR) and nortriptyline in patients with FD after 4 weeks of treatment.<h4>Methods</h4>Participants with FD were randomly assigned (1:1) to receive mosapride CR (mosapride CR 15 mg and nortriptyline placebo) or nortriptyline (mosapride CR placebo and nortriptyline 10 mg) in double-placebo, double-blinded, randomized controlled, parallel clinical study. The primary endpoint was defined as the proportion of patients with overall dyspepsia improvement after 4 weeks treatment. The secondary endpoints were changes in individual symptom scores, anxiety, depression, an"],"journal":["Journal of neurogastroenterology and motility"],"pubmed_title":["Clinical Trial: Efficacy of Mosapride Controlled-release and Nortriptyline in Patients With Functional Dyspepsia: A Multicenter, Double-placebo, Double-blinded, Randomized Controlled, Parallel Clinical Study."],"pmcid":["PMC10774802"],"funding_grant_id":["2018(CT)-KUP-018"],"pubmed_authors":["Kwon JG","Bang KB","Song KH","Huh CW","Park JK","Shin CM","Kim JW","Oh JH","Lee JY","Functional Dyspepsia Research Group under the Korean Society of Neurogastroenterology and Motility","Tae CH","Youn YH","Cha RR","Gweon TG"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Trial: Efficacy of Mosapride Controlled-release and Nortriptyline in Patients With Functional Dyspepsia: A Multicenter, Double-placebo, Double-blinded, Randomized Controlled, Parallel Clinical Study.","description":"<h4>Background/aims</h4>Prokinetic agents and neuromodulators are among the treatment options for functional dyspepsia (FD), but their comparative efficacy is unclear. We aimed to compare the efficacy of mosapride controlled-release (CR) and nortriptyline in patients with FD after 4 weeks of treatment.<h4>Methods</h4>Participants with FD were randomly assigned (1:1) to receive mosapride CR (mosapride CR 15 mg and nortriptyline placebo) or nortriptyline (mosapride CR placebo and nortriptyline 10 mg) in double-placebo, double-blinded, randomized controlled, parallel clinical study. The primary endpoint was defined as the proportion of patients with overall dyspepsia improvement after 4 weeks treatment. The secondary endpoints were changes in individual symptom scores, anxiety, depression, an","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan","modification":"2025-04-22T20:17:27.75Z","creation":"2025-04-06T03:01:54.32Z"},"accession":"S-EPMC10774802","cross_references":{"pubmed":["38173162"],"doi":["10.5056/jnm23147"]}}